# Pilot Study of Reduced Venetoclax Exposure

> **NCT07163793** · PHASE2 · RECRUITING · sponsor: **Northwell Health** · enrollment: 41 (estimated)

## Conditions studied

- Acute Myeloid Leukemia in Remission

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Decitabine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07163793
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-07
- **Primary completion:** 2026-10
- **Final completion:** 2028-10
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07163793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07163793, "Pilot Study of Reduced Venetoclax Exposure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07163793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*